[go: up one dir, main page]

BR9606766A - Utilização de compostos e processo para o tratamento e profilaxia de disturbios degenerativos cerebrais - Google Patents

Utilização de compostos e processo para o tratamento e profilaxia de disturbios degenerativos cerebrais

Info

Publication number
BR9606766A
BR9606766A BR9606766A BR9606766A BR9606766A BR 9606766 A BR9606766 A BR 9606766A BR 9606766 A BR9606766 A BR 9606766A BR 9606766 A BR9606766 A BR 9606766A BR 9606766 A BR9606766 A BR 9606766A
Authority
BR
Brazil
Prior art keywords
prophylaxis
compounds
treatment
degenerative brain
brain disorders
Prior art date
Application number
BR9606766A
Other languages
English (en)
Inventor
Niels Korsgaard
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of BR9606766A publication Critical patent/BR9606766A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
BR9606766A 1995-01-20 1996-01-10 Utilização de compostos e processo para o tratamento e profilaxia de disturbios degenerativos cerebrais BR9606766A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK6895 1995-01-20
DK77695 1995-06-30
PCT/DK1996/000010 WO1996022091A1 (en) 1995-01-20 1996-01-10 Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of cerebral degenerative disorders

Publications (1)

Publication Number Publication Date
BR9606766A true BR9606766A (pt) 1997-12-30

Family

ID=26063233

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9606766A BR9606766A (pt) 1995-01-20 1996-01-10 Utilização de compostos e processo para o tratamento e profilaxia de disturbios degenerativos cerebrais

Country Status (13)

Country Link
US (2) US5696149A (pt)
EP (1) EP0809495A1 (pt)
JP (1) JPH10512269A (pt)
KR (1) KR19980701549A (pt)
CN (1) CN1168101A (pt)
AU (1) AU4328896A (pt)
BR (1) BR9606766A (pt)
CA (1) CA2208856A1 (pt)
CZ (1) CZ212097A3 (pt)
HU (1) HUP9702246A3 (pt)
IL (1) IL116828A (pt)
NO (1) NO973342L (pt)
WO (1) WO1996022091A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2233888A1 (en) 1995-10-06 1997-04-10 Ligand Pharmaceuticals Incorporated Dimer-selective rxr modulators and methods for their use
US5756539A (en) * 1996-07-11 1998-05-26 Novo Nordis A/S 3, 4-diphenyl chromans for inhibiting one or more psychiatric disorders
US5958967A (en) * 1996-10-28 1999-09-28 Novo Nordisk A/S Cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
WO1998032437A1 (en) * 1997-01-29 1998-07-30 Novo Nordisk A/S Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for inhibiting one or more psychiatric disorders
US8080675B2 (en) 2004-09-21 2011-12-20 Marshall Edwards, Inc. Chroman derivatives, medicaments and use in therapy
EP1794141B1 (en) 2004-09-21 2011-11-09 Marshall Edwards, Inc. Substituted chroman derivatives, medicaments and use in therapy
EP2120925A4 (en) * 2007-03-16 2010-04-07 Novogen Res Pty Ltd METHOD FOR INTRODUCING AUTOPHAGIA
KR20110101135A (ko) * 2008-10-22 2011-09-15 노보겐 리서치 피티와이 리미티드 예정 세포 사멸을 유도하는 방법
US9708283B2 (en) 2010-11-01 2017-07-18 Mei Pharma, Inc. Isoflavonoid compositions and methods for the treatment of cancer
SI2953938T1 (en) 2014-02-07 2018-01-31 Novogen Ltd. Functionalized benzopyran compounds and their use
CN116139125A (zh) 2015-02-02 2023-05-23 梅制药公司 联合治疗

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3822287A (en) * 1969-04-17 1974-07-02 Rexall Drug Chemical Process for preparation of substituted 3,4-(diphenyl)chromans
US4447622A (en) * 1981-09-22 1984-05-08 Council Of Scientific And Industrial Research Rafi Marg Preparation of l- and d-isomers of dl-3,4-trans-2,2-disubstituted-3,4-diarylchromans and derivatives thereof
US5280040A (en) * 1993-03-11 1994-01-18 Zymogenetics, Inc. Methods for reducing bone loss using centchroman derivatives
US5451603A (en) * 1993-03-11 1995-09-19 Zymogenetics, Inc. 3,4-diarylchromans for treatment of dermatitis
DE4311870C2 (de) * 1993-04-10 1998-07-30 Altramed Holdings Ltd Verwendung eines Anti-Östrigens zur Therapie und Prophylaxe von Demenz-Erkrankungen
DE4320896A1 (de) * 1993-06-24 1995-01-05 Denecke Rainer Dr Med Vet Präparat zur Therapie und Prophylaxe von Demenz-Erkrankungen
US5554601A (en) * 1993-11-05 1996-09-10 University Of Florida Methods for neuroprotection

Also Published As

Publication number Publication date
US5827873A (en) 1998-10-27
CZ212097A3 (en) 1997-11-12
WO1996022091A1 (en) 1996-07-25
IL116828A0 (en) 1996-05-14
EP0809495A1 (en) 1997-12-03
HUP9702246A2 (hu) 1998-12-28
NO973342D0 (no) 1997-07-18
MX9705390A (es) 1997-10-31
US5696149A (en) 1997-12-09
JPH10512269A (ja) 1998-11-24
IL116828A (en) 1999-11-30
CN1168101A (zh) 1997-12-17
HUP9702246A3 (en) 1999-12-28
CA2208856A1 (en) 1996-07-25
NO973342L (no) 1997-07-18
KR19980701549A (ko) 1998-05-15
AU4328896A (en) 1996-08-07

Similar Documents

Publication Publication Date Title
BR9407869A (pt) Combinaçao composiçao farmacêutica e processo para o tratamento de osteoporose
BR9610117A (pt) Processo para o tratamento de partículas finas de óxido metálico
BR9305274A (pt) Processo para tratar leite cru
BR9408148A (pt) Processo para tratamento de arritmia composto e formulação farmacêutica
PT861081E (pt) Utilizacao de epinastina para o tratamento de dores
BR9400571A (pt) Processo para o tratamento de despejo orgânico
BR9602695A (pt) Composto método e composição para tratamento de distúrbios hiperproliferativos
BR9503559A (pt) Composição cosmeticamente aceitável processo para o tratamento de acne vulgaris composição para maquiagem facial
BR9510077A (pt) Aparelho e processo para tratamento e distribuição de águas servidas
BR9503812A (pt) Composto composição farmacêutica utilização método de tratamento de um ser humano processo para a preparação de um composto
BR9506271A (pt) Processo para o tratamento de aves domésticas
PT96725A (pt) Processo para o tratamento de graos de cacau
BR9708093A (pt) Composto formulação uso composto e processo para tratamento de distúrbios mediados por 5-hidroxitriptamina e para preparação do composto
BR9606766A (pt) Utilização de compostos e processo para o tratamento e profilaxia de disturbios degenerativos cerebrais
BR9607413A (pt) Processo para produçao de pentafluoretano e tetrafluorcloroetano
BR9602337A (pt) Composto processo para sua preparação usos do mesmo processo para tratamento de arritmias e medicamento
BR9002081A (pt) Processo e aparelho para o tratamento de detritos organicos
BR9606925A (pt) Utilização de compostos e processo para o tratamento e profilaxia da obesidade
BR9611396A (pt) Composto para tratamento de lesão cerebral traumática
PT719499E (pt) Processo de tratamento anti-germinativo de tuberculos ou bolbos
IS1919B (is) Bensamíð til að meðhöndla taugahrörnunarsjúkdóma
BR9101496A (pt) Processo para tratamento de tecidos
BR9307043A (pt) Processo para preparação de dinitro-tolueno
BR9606754A (pt) Uso de compostos processo para tratamento e profilaxia de ginecomastia idiopática ou fisiológia e novo detalhe característico ou combinação de detalhes
BR9205493A (pt) Composicao farmaceutica e processo para fabricacao de composicao farmaceutica

Legal Events

Date Code Title Description
EG Technical examination (opinion): publication of technical examination (opinion)
FC Decision: refusal